BACKGROUND: Prognostic factors (e.g., gender, tumor stage, and hypoxia) have an impact on survival in patients with head and neck cancer. Thus, the impact of physical status and comorbidities on treatment decision and survival were evaluated. PATIENTS AND METHODS: A total of 169 primary, inoperable patients with squamous cell cancer of the head and neck were retrospectively investigated. Patients were treated with hyperfractionated accelerated radio(chemo)therapy (HARcT) or hypofractionated radio(chemo)therapy (HypoRcT). Depending on the individual patient's situation (Karnofsky Performance Index, KPI), treatment for patients with a KPI of 80-100% was generally radiochemotherapy and for patients with a KPI ≤ 70% treatment was radiotherapy alone. In addition, all comorbidities were evaluated. Uni- and multivariate proportional hazards model were used, and overall survival (OS) was estimated by the Kaplan-Meier method. RESULTS: Treatment consisted of HARcT for 76 patients (45%), HART for 28 patients (17%), HypoRcT for 14 patients(8%), and HypoRT for 51 patients (30%). Of the patients, 107 patients (63%) presented with a KPI of 80-100%. OS (20%) was significantly better for patients with a KPI of 80-100%, while the OS for patients with a KPI ≤ 70% was 8% (p < 0.001). Good KPI, total irradiation dose (> 70 Gy), and chemotherapy were significant prognostic factors for better OS. CONCLUSION: Our retrospective analysis shows that performance status with dependency on comorbidities was an independent risk factor for OS.
BACKGROUND: Prognostic factors (e.g., gender, tumor stage, and hypoxia) have an impact on survival in patients with head and neck cancer. Thus, the impact of physical status and comorbidities on treatment decision and survival were evaluated. PATIENTS AND METHODS: A total of 169 primary, inoperable patients with squamous cell cancer of the head and neck were retrospectively investigated. Patients were treated with hyperfractionated accelerated radio(chemo)therapy (HARcT) or hypofractionated radio(chemo)therapy (HypoRcT). Depending on the individual patient's situation (Karnofsky Performance Index, KPI), treatment for patients with a KPI of 80-100% was generally radiochemotherapy and for patients with a KPI ≤ 70% treatment was radiotherapy alone. In addition, all comorbidities were evaluated. Uni- and multivariate proportional hazards model were used, and overall survival (OS) was estimated by the Kaplan-Meier method. RESULTS: Treatment consisted of HARcT for 76 patients (45%), HART for 28 patients (17%), HypoRcT for 14 patients(8%), and HypoRT for 51 patients (30%). Of the patients, 107 patients (63%) presented with a KPI of 80-100%. OS (20%) was significantly better for patients with a KPI of 80-100%, while the OS for patients with a KPI ≤ 70% was 8% (p < 0.001). Good KPI, total irradiation dose (> 70 Gy), and chemotherapy were significant prognostic factors for better OS. CONCLUSION: Our retrospective analysis shows that performance status with dependency on comorbidities was an independent risk factor for OS.
Authors: Volker Budach; Martin Stuschke; Wilfried Budach; Michael Baumann; Dirk Geismar; Gerhard Grabenbauer; Ingrid Lammert; Klaus Jahnke; Georg Stueben; Thomas Herrmann; Michael Bamberg; Peter Wust; Wolfgang Hinkelbein; Klaus-Dieter Wernecke Journal: J Clin Oncol Date: 2005-02-20 Impact factor: 44.544
Authors: Hendrik Andreas Wolff; Jan Bosch; Klaus Jung; Tobias Overbeck; Steffen Hennies; Christoph Matthias; Clemens F Hess; Ralph M Roedel; Hans Christiansen Journal: Strahlenther Onkol Date: 2010-04-26 Impact factor: 3.621
Authors: Jürgen Dunst; Peter Stadler; Axel Becker; Christine Lautenschläger; Tanja Pelz; Gabriele Hänsgen; Michael Molls; Thomas Kuhnt Journal: Strahlenther Onkol Date: 2003-08 Impact factor: 3.621
Authors: Ulrich Schäfer; Oliver Micke; Stefan Bodo Müller; Patrick Schüller; Normann Willich Journal: Strahlenther Onkol Date: 2003-08 Impact factor: 3.621
Authors: L Miszczyk; B Maciejewski; A Tukiendorf; G Woźniak; B Jochymek; A Gawryszuk; M Szweda Journal: Br J Radiol Date: 2014-07-16 Impact factor: 3.039
Authors: P Balermpas; C Bauer; I Fraunholz; A Ottinger; J Wagenblast; T Stöver; O Seitz; E Fokas; C Rödel; C Weiss Journal: Strahlenther Onkol Date: 2014-01-12 Impact factor: 3.621
Authors: J O Brömme; M Schmücking; A Arnold; R Giger; D Rauch; D Leiser; L Plasswilm; A Geretschläger; P Ghadjar; D M Aebersold Journal: Strahlenther Onkol Date: 2013-07-04 Impact factor: 3.621
Authors: V Budach; E-T Becker; D Boehmer; H Badakhshi; U Jahn; K-D Wernecke; C Stromberger Journal: Strahlenther Onkol Date: 2013-12-11 Impact factor: 3.621
Authors: T Rutkowski; A Wygoda; K Składowski; B Hejduk; R Rutkowski; Z Kołosza; B Maciejewski Journal: Strahlenther Onkol Date: 2013-08-29 Impact factor: 3.621
Authors: Sarah Schimansky; Samantha Lang; Rhona Beynon; Christopher Penfold; Amy Davies; Andrea Waylen; Steve Thomas; Miranda Pring; Michael Pawlita; Tim Waterboer; Andy Ness Journal: Head Neck Date: 2018-12-14 Impact factor: 3.147